US strategy for state-owned patents under increasing scrutiny amidst drug price controversies
The government is facing calls to better leverage its own IP in the public interest following revelations about PrEP rights
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.